The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome

Απλή σελίδα τεκμηρίου
dc.contributor.authorFilippatos, T. D.en
dc.contributor.authorLiberopoulos, E. N.en
dc.contributor.authorKostapanos, M.en
dc.contributor.authorGazi, I. F.en
dc.contributor.authorPapavasiliou, E. C.en
dc.contributor.authorKiortsis, D. N.en
dc.contributor.authorTselepis, A. D.en
dc.contributor.authorElisaf, M. S.en
dc.date.accessioned2015-11-24T16:50:35Z
dc.date.available2015-11-24T16:50:35Z
dc.identifier.issn1462-8902-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/9623
dc.rightsDefault Licence-
dc.subjectfenofibrateen
dc.subjecthdl subfractionsen
dc.subjectmetabolic syndromeen
dc.subjectorlistaten
dc.subjectpre-beta1-hdlen
dc.subjectsandwich enzyme-immunoassayen
dc.subjectlow-fat dieten
dc.subjectintervention trialen
dc.subjectcholesterol effluxen
dc.subjectdiabetic-patientsen
dc.subjecthepatic lipaseen
dc.subjecthdlen
dc.subjectpre-beta-1-hdlen
dc.subjectsubclassesen
dc.subjectinsulinen
dc.titleThe effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndromeen
heal.abstractObjective: We assessed the effect of orlistat and fenofibrate, alone or in combination, on plasma high-density lipoprotein (HDL) subfractions and plasma pre-beta1-HDL levels in overweight and obese subjects with metabolic syndrome (MetS). Methods: Patients (n = 89) were prescribed a low-fat low-calorie diet and were randomly allocated to receive orlistat 120 mg three times daily (O group), micronized fenofibrate 200 mg/day (F group) or both (OF group) for 6 months. HDL subfractions were determined using a polyacrylamide gel tube electrophoresis method and pre-beta1-HDL levels using enzyme-linked immunoabsorbent assay. Results: We observed a significant change of high-density lipoprotein cholesterol (HDL-C) levels only in the F group (+3%, p < 0.05). Large HDL-C levels were significantly increased and small HDL-C levels were significantly reduced with O administration. In F group we observed a significant increase of small HDL-C levels. No significant change of large or small HDL-C levels was observed with combination treatment. We observed a significant increase of pre-beta1-HDL levels in all groups, which was significantly greater in OF group compared with O or F monotherapy. Conclusion: OF combination increased the antiatherogenic pre-beta1-HDL levels in overweight and obese patients with MetS. Furthermore, OF combination counterbalanced the reduction of small HDL-C levels observed with orlistat monotherapy.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primaryDOI 10.1111/j.1463-1326.2007.00733.x-
heal.identifier.secondary<Go to ISI>://000255602500005-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/store/10.1111/j.1463-1326.2007.00733.x/asset/j.1463-1326.2007.00733.x.pdf?v=1&t=h0f7uumw&s=99a398f9b534f6360017792a0a3169303b484abd-
heal.journalNameDiabetes Obesity & Metabolismen
heal.journalTypepeer reviewed-
heal.languageen-
heal.publicationDate2008-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ